U.S. regulators have extended their review of Merck & Co's application to expand the use of its cervical cancer vaccine to an older group of women, and are now expected to act by year end, the drugmaker said on Wednesday. Full story
Drugmaker Merck & Co. on Thursday posted a bigger profit in the third quarter due to slightly higher sales and a huge gain from selling a business. Full story
One in three teenage girls have rolled up their sleeves for a vaccine against cervical cancer, but vaccination rates vary dramatically between states, according to a new federal report. Full story
Federal health officials favor approving GlaxoSmithKline's long-delayed vaccine Cervarix to prevent the leading cause of cervical cancer in U.S. women. Full story
A vaccine from GlaxoSmithKline blocks the virus that causes most cases of cervical cancer, the U.S. Food and Drug Administration said Friday. Full story
Only Virginia and the District of Columbia have moved toward requiring sixth-grade girls to get vaccinated for a potentially cancerous sexually transmitted disease. Full story
